DepYmed
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3 Bioscience Park Dr, Farmingdale, New Y...Phone Number
(516) 662-8749Website
www.depymedinc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About DepYmed
DepYmed is focused on developing potent inhibitors of the enzyme PTP1B as potential therapeutic agents for various diseases, including Rett Syndrome, Wilson Disease, and cancer. The company is advancing two orally bioavailable small molecules into clinical trials targeting these conditions. Additionally, DepYmed is building a library of selective PTP1B inhibitors with therapeutic potential for other major metabolic, inflammatory, and neurodegenerative diseases. Their innovative approach harnesses the role of protein tyrosine phosphatases in disease pathology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DepYmed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
DepYmed, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when DepYmed launches new products
Earning: See what the market has to say on DepYmed recently announced quarterly report
Click to see if DepYmed had a recent Job posting/layoffs
Check if DepYmed has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once DepYmed has new funding data
Congratulate Masked Content for being promoted to Masked Content at DepYmed
Website visits: Recent activity has been detected on your website
Check out if DepYmed is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to DepYmed
Compare insights from companies similar to DepYmed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
DepYmed
<$5M
1-10
Private
-
2014
N/A
Company Profile Activity
Activity Insights
DepYmed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
DepYmed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about DepYmed.
DepYmed Tech Stack
A closer look at the technologies used by DepYmed
See more technologies
DepYmed News & Media
DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
Data were presented to demonstrate that DPM-1003 provides a mechanism-based approach to the treatment of Rett Syndrome and is poised to enter clinical development in 2024 Data were presented to demonstrate that DPM-1003 provides a mechanism-based approach to the treatment of Rett Syndrome and is poised to enter clinical development in 2024DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes. Today DepYmed announces it will be presenting two abstracts on its small molecule PTP1B inhibitor program at the 2023 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting. The confDepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology based upon targeting the protein tyrosine phosphatase (PTP) family of enzymes. Today, DepYmed announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its lead clinical candidate, a small molecule PTP1B inhibitor for the treatment of patients wiDepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease
FARMINGDALE, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology, based upon targeting the protein tyrosine phosphatase (PTP) family of enzymes. Today, the Company announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its clinical candidate DPM-1001, a small molecule PTP1B inhibitor that also has hig
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DepYmed
Sign Up For FreeTo access detailed company insights
DepYmed is focused on developing potent inhibitors of the enzyme PTP1B as potential therapeutic agents for various diseases, including Rett Syndrome, Wilson Disease, and cancer. The company is advancing two orally bioavailable small molecules into clinical trials targeting these conditions. Additionally, DepYmed is building a library of selective P... Read More
